Health ❯ Healthcare ❯ Pharmaceuticals ❯ Weight Loss

Orforglipron

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

The once-daily small-molecule pill can be taken without empty-stomach restrictions.

Lilly’s Orforglipron Pill Hits Phase 3 Goals and Outperforms Oral Semaglutide in Diabetes Study

Lilly’s Oral GLP-1 Pill Underperforms Wegovy in Late-Stage Trial